GHRS
Price
$9.54
Change
+$0.54 (+6.00%)
Updated
Apr 30 closing price
Capitalization
558.25M
13 days until earnings call
MDGL
Price
$333.91
Change
-$6.89 (-2.02%)
Updated
Apr 30 closing price
Capitalization
7.41B
Earnings call today
Ad is loading...

GHRS vs MDGL

Header iconGHRS vs MDGL Comparison
Open Charts GHRS vs MDGLBanner chart's image
GH Research
Price$9.54
Change+$0.54 (+6.00%)
Volume$228.73K
Capitalization558.25M
Madrigal Pharmaceuticals
Price$333.91
Change-$6.89 (-2.02%)
Volume$416.62K
Capitalization7.41B
GHRS vs MDGL Comparison Chart
Loading...
GHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GHRS vs. MDGL commentary
May 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GHRS is a Hold and MDGL is a Buy.

Ad is loading...
COMPARISON
Comparison
May 01, 2025
Stock price -- (GHRS: $9.57 vs. MDGL: $333.91)
Brand notoriety: GHRS and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GHRS: 95% vs. MDGL: 110%
Market capitalization -- GHRS: $558.25M vs. MDGL: $7.41B
GHRS [@Biotechnology] is valued at $558.25M. MDGL’s [@Biotechnology] market capitalization is $7.41B. The market cap for tickers in the [@Biotechnology] industry ranges from $279.46B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GHRS’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 1 green FA rating(s).

  • GHRS’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 1 green, 4 red.
According to our system of comparison, MDGL is a better buy in the long-term than GHRS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GHRS’s TA Score shows that 5 TA indicator(s) are bullish while MDGL’s TA Score has 4 bullish TA indicator(s).

  • GHRS’s TA Score: 5 bullish, 4 bearish.
  • MDGL’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, GHRS is a better buy in the short-term than MDGL.

Price Growth

GHRS (@Biotechnology) experienced а +0.74% price change this week, while MDGL (@Biotechnology) price change was +8.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.45%. For the same industry, the average monthly price growth was +5.12%, and the average quarterly price growth was -6.68%.

Reported Earning Dates

GHRS is expected to report earnings on Aug 20, 2025.

MDGL is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+4.45% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($7.41B) has a higher market cap than GHRS($558M). GHRS YTD gains are higher at: 36.714 vs. MDGL (8.212). GHRS has higher annual earnings (EBITDA): -38.6M vs. MDGL (-450.12M). MDGL has more cash in the bank: 926M vs. GHRS (149M). GHRS has less debt than MDGL: GHRS (624K) vs MDGL (120M). MDGL has higher revenues than GHRS: MDGL (180M) vs GHRS (0).
GHRSMDGLGHRS / MDGL
Capitalization558M7.41B8%
EBITDA-38.6M-450.12M9%
Gain YTD36.7148.212447%
P/E RatioN/AN/A-
Revenue0180M-
Total Cash149M926M16%
Total Debt624K120M1%
FUNDAMENTALS RATINGS
MDGL: Fundamental Ratings
MDGL
OUTLOOK RATING
1..100
7
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
PROFIT vs RISK RATING
1..100
27
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
40
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GHRSMDGL
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Momentum
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
70%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
74%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
75%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 9 days ago
90%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 11 days ago
80%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
77%
View a ticker or compare two or three
Ad is loading...
GHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JCE14.250.07
+0.49%
Nuveen Core Equity Alpha Fund
XTJA26.600.04
+0.15%
Innovator US Equity Acclrtd Pls ETF Jan
EOI18.790.02
+0.11%
Eaton Vance Enhanced Equity Income Fund
IOO96.14-0.03
-0.03%
iShares Global 100 ETF
EMC26.41-0.03
-0.11%
Global X Emerging Mkts Great Cnsmr ETF

GHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GHRS has been loosely correlated with MDGL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if GHRS jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GHRS
1D Price
Change %
GHRS100%
+6.33%
MDGL - GHRS
43%
Loosely correlated
-2.02%
IVVD - GHRS
40%
Loosely correlated
-0.82%
ATAI - GHRS
36%
Loosely correlated
+6.38%
IBRX - GHRS
31%
Poorly correlated
+0.80%
ORMP - GHRS
31%
Poorly correlated
-0.43%
More

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with KANT. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then KANT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
-2.02%
KANT - MDGL
62%
Loosely correlated
-2.29%
ALXO - MDGL
56%
Loosely correlated
+5.88%
ZNTL - MDGL
51%
Loosely correlated
+2.92%
CGEM - MDGL
50%
Loosely correlated
+4.81%
TSVT - MDGL
50%
Loosely correlated
N/A
More